Podcasts about conference coverage

Guest: Gary S. Firestein, MD While cadherin-6 may not yet shift clinical practice in rheumatoid arthritis, its role as a surface-expressed, actionable target opens the door to rapid therapeutic development—particularly with existing antibodies already in clinical trials for urologic cancers. Dr. Gary Firestein discusses the potential for cadherin-6 to become a useful target across multiple diseases. Dr. Firestein is a Distinguished Professor of Medicine and the Senior Associate Vice Chancellor for Health Sciences at UC San Diego.

Guest: Sujith Cherian MD, FCCP, DAABIP Obesity impacts how the lungs function in a variety of ways, and understanding these impacts is essential for interpreting pulmonary function tests, identifying restrictive or obstructive patterns, and managing ventilation. Learn more with Dr. Sujith Cherian, who's an Associate Professor in the Divisions of Critical Care, Pulmonary, and Sleep Medicine at University of Texas Health-McGovern Medical School and the Director of Interventional Pulmonology and Pleural Diseases at Lyndon B. Johnson Hospital in Houston. He also spoke about this topic at the 2025 CHEST Annual Meeting.

Guest: Gary S. Firestein, MD Despite advances in biologics, many patients with rheumatoid arthritis still experience persistent inflammation. However, cadherin-6 has recently been identified as a potential treatment target. Hear from Dr. Gary Firestein as he explains the discovery, function, and therapeutic potential of cadherin-6 in rheumatoid arthritis pathogenesis. Dr. Firestein is a Distinguished Professor of Medicine and the Senior Associate Vice Chancellor for Health Sciences at UC San Diego.

Guest: David Feller-Kopman, MD Cytology via thoracentesis remains the first-line approach for diagnosing malignant pleural effusion (MPE), yet its sensitivity is limited. leaving many patients undiagnosed or delayed in treatment. In this expert-led discussion, Dr. David Feller-Kopman explores the limitations of current diagnostic methods and the evolving role of biomarkers in enhancing both diagnostic accuracy and prognostic insight. Dr. Feller-Kopman is a Professor of Medicine at the Geisel School of Medicine at Dartmouth and the Chief of Pulmonary and Critical Care Medicine at Dartmouth-Hitchcock Medical Center, and he discussed this topic at the 2025 CHEST Annual Meeting.

Guest: Jaime Moore, MD Discussing weight with pediatric patients and families is a nuanced challenge shaped by stigma, culture, and access—but it's also a vital opportunity for early intervention. Dr. Jaime Moore shares how to build confidence, counter bias, and leverage practical tools and partnerships that support long-term, personalized care. Dr. Moore is an Assistant Professor of Pediatric Nutrition at the University of Colorado Anschutz School of Medicine and part of the Children's Hospital Colorado Lifestyle Medicine Program. She also spoke about this topic at the 2025 American Academy of Pediatrics (AAP) National Conference and Exhibition.

Host: Ryan Quigley New research presented at the 2025 American College of Rheumatology Convergence highlights a critical link between adverse childhood experiences and mental health outcomes in adolescents with childhood-onset systemic lupus erythematosus (cSLE). In this AudioAbstract, Ryan Quigley explores the findings, the implications for trauma-informed care, and the need to assess psychosocial history in managing cSLE.

Guest: Eric Ruderman, MD Combined dermatology–rheumatology clinics are transforming psoriatic disease care by streamlining communication, reducing patient burden, and enabling more targeted, effective treatments. To learn more about how these clinks work and why they matter for patients with psoriatic disease, tune in to hear from Dr. Eric Ruderman, Professor of Medicine and the Associate Chief of Clinical Affairs for the Division of Rheumatology at Northwestern University Feinberg School of Medicine.

Host: Ryan Quigley In a 2025 study investigating salivary metabolites as potential biomarkers in cystic fibrosis, researchers identified distinct metabolic patterns linked with key complications as well as correlations with lung function. In this AudioAbstract, Ryan Quigley discusses how a simple saliva sample could provide clinicians with an accessible, non-invasive tool to stratify patients, monitor therapies, and advance personalized care in cystic fibrosis. This topic was also discussed at the 2025 CHEST Annual Meeting.

Guest: Jennifer M. Kalish, MD, PhD, FAAP Early genetic evaluation plays a vital role in identifying potential causes of neurodevelopmental disorders and guiding families on next steps, expectations, and recurrence risks. Dr. Jennifer Kalish joins us to share practical insights for recognizing when to initiate testing, selecting the right tests, and addressing barriers such as insurance and interpretation. Dr. Kalish is an Assistant Professor of Pediatrics at the University of Pennsylvania Perelman School of Medicine and the Director of the Beckwith-Wiedemann Syndrome Program at the Children's Hospital of Philadelphia. She also spoke about this topic at the 2025 American Academy of Pediatrics (AAP) National Conference and Exhibition.

Host: Shelina Ramnarine, PhD Guest: Yolanda N. Evans, MD, FAAP Recognizing how inequities can significantly impact pediatric care outcomes is essential to improving access, trust, and long-term health. Dr. Shelina Ramnarine is joined by Dr. Yolanda Evans to discuss actionable strategies that can help us deliver more inclusive care, from social determinant screeners to equity-focused frameworks. Dr. Evans is a board-certified pediatrician and adolescent medicine specialist practicing in Seattle, Washington, and she spoke about this topic at the 2025 American Academy of Pediatrics National Conference and Exhibition.

Host: Ryan Quigley Guest: Heather Forkey, MD Guest: Wynne Morgan, MD Childhood trauma can profoundly alter brain and behavioral development, making it essential to recognize how trauma differs from other diagnoses like ADHD. Ryan Quigley sits down with Drs. Heather Forkey and Wynne Morgan, who presented on this topic at the 2025 American Academy of Pediatrics National Conference and Exhibition, to better understand how to identify trauma responses, avoid misdiagnosis, and implement supportive treatment strategies that prioritize safety, routine, and caregiver connection. Dr. Forkey is a Professor of Pediatrics and Vice Chair of Pediatrics and Dr. Morgan is an Assistant Professor in the Departments of Psychiatry and Behavioral Sciences at UMass Chan Medical School in Worcester, Massachusetts.

Guest: Sergio Baranzini, PhD In a landmark study involving over 10,000 patients, the International MS Genetics Consortium (IMSGC) has identified the first genetic variant associated with disease severity in multiple sclerosis (MS). Dr. Sergio Baranzini, a Distinguished Professor of Neurology at the University of California, San Francisco Weill Institute for Neurosciences, explains what's next in researching this variant and working towards effective treatments. Dr. Baranzini also spoke on this topic at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Guest: Michael Levy, MD, PhD Antibody-mediated demyelinating diseases, such as neuromyelitis optica spectrum disorder and MOG antibody disease, differ fundamentally from multiple sclerosis (MS) due to their association with specific antibodies. Dr. Michael Levy explains how these conditions progress, how relapses can drive disability, and why prevention is critical for improving long-term outcomes. Dr. Levy is an Associate Professor at Harvard Medical School working in the Department of Neurology at Brigham and Women's Hospital, and he spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.

Guest: Le Hua, MD Diagnosing multiple sclerosis (MS) in older patients presents unique challenges, especially as age-related comorbidities and common neurological findings often mimic MS. Hear from Dr. Le Hua as she highlights the importance of thorough clinical history, cautious interpretation of imaging, and the role of paraclinical studies in ensuring accurate MS diagnosis, particularly in patients over 50. Dr. Hua is the Director of Clinical Operations and Director of the Multiple Sclerosis Program at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. She also spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.

Guest: Sergio Baranzini, PhD In a landmark study involving over 10,000 patients, the International MS Genetics Consortium (IMSGC) has identified the first genetic variant associated with disease severity in multiple sclerosis (MS). Dr. Sergio Baranzini, a Distinguished Professor of Neurology at the University of California, San Francisco Weill Institute for Neurosciences, explains what's next in researching this variant and working towards effective treatments. Dr. Baranzini also spoke on this topic at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Guest: Le Hua, MD Diagnosing multiple sclerosis (MS) in older patients presents unique challenges, especially as age-related comorbidities and common neurological findings often mimic MS. Hear from Dr. Le Hua as she highlights the importance of thorough clinical history, cautious interpretation of imaging, and the role of paraclinical studies in ensuring accurate MS diagnosis, particularly in patients over 50. Dr. Hua is the Director of Clinical Operations and Director of the Multiple Sclerosis Program at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. She also spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.

Guest: Michael Levy, MD, PhD Antibody-mediated demyelinating diseases, such as neuromyelitis optica spectrum disorder and MOG antibody disease, differ fundamentally from multiple sclerosis (MS) due to their association with specific antibodies. Dr. Michael Levy explains how these conditions progress, how relapses can drive disability, and why prevention is critical for improving long-term outcomes. Dr. Levy is an Associate Professor at Harvard Medical School working in the Department of Neurology at Brigham and Women's Hospital, and he spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.

Host: Ryan Quigley Neonatal food protein-induced enterocolitis syndrome (N-FPIES) is an underrecognized condition often misdiagnosed as necrotizing enterocolitis, despite distinct clinical and lab features that demand a different treatment approach. In this AudioAbstract, ReachMD's Ryan Quigley explores the early signs, immune pathways, and diagnostic markers of N-FPIES, offering essential insights to help pediatric clinicians identify this condition and initiate appropriate dietary management to avoid unnecessary interventions.

Guest: Leonard H. Calabrese, DO Preventing serious infections should be a priority when treating patients with immune-mediated inflammatory diseases, especially those receiving immunosuppressive therapies. By assessing patients' level of immunocompetence, clinicians can better tailor vaccination strategies and optimize infection prevention. Hear Dr. Leonard Calabrese discuss how to evaluate immunosuppression risk and coordinate timely vaccinations for patients undergoing immunomodulatory treatments. Dr. Calabrese heads the Section of Clinical Immunology at the Cleveland Clinic in Ohio, where he manages the Clinical Immunology Clinic and is on the staff of the Department of Rheumatic and Immunologic Diseases. He also spoke on this topic at the 2025 Congress of Clinical Rheumatology West conference.

Guest: Laura B. Enyedi, MD Pediatricians are often the first to encounter eye conditions that can range from common to life-threatening. Hear from Dr. Laura Enyedi as she shares highlights from her presentation on diagnosing childhood ocular disorders from the 2025 American Academy of Pediatrics (AAP) National Conference and Exhibition. Dr. Enyedi is a Professor of Ophthalmology and an Associate Professor in Pediatrics at Duke University School of Medicine in Durham, North Carolina.

Host: Hallie Blevins, PhD. Early resistance to hydroxyurea in patients with polycythemia vera (PV) is associated with higher risks of thromboembolic complications, disease progression, and mortality. The PV-AIM study applied machine learning to real-world data and identified simple lab-based predictors that stratify patients by risk, and these findings were later validated in the HU-F-AIM trial. Hear from ReachMD's Dr. Hallie Blevins as she dives into the results and explains implications for optimized therapy and improved long-term outcomes.

Host: Ryan Quigley A new multicenter study highlights how serum and CSF biomarkers can refine prognostic accuracy and guide treatment strategies in multiple sclerosis (MS). ReachMD's Ryan Quigley explains key findings and provides insights on how integrating these biomarkers at diagnosis could move MS care toward more personalized and effective interventions. This topic was also discussed at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Host: Ryan Quigley A new multicenter study highlights how serum and CSF biomarkers can refine prognostic accuracy and guide treatment strategies in multiple sclerosis (MS). ReachMD's Ryan Quigley explains key findings and provides insights on how integrating these biomarkers at diagnosis could move MS care toward more personalized and effective interventions. This topic was also discussed at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Host: Hallie Blevins, PhD. Early resistance to hydroxyurea in patients with polycythemia vera (PV) is associated with higher risks of thromboembolic complications, disease progression, and mortality. The PV-AIM study applied machine learning to real-world data and identified simple lab-based predictors that stratify patients by risk, and these findings were later validated in the HU-F-AIM trial. Hear from ReachMD's Dr. Hallie Blevins as she dives into the results and explains implications for optimized therapy and improved long-term outcomes.

Host: Ryan Quigley In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.

Host: Ryan Quigley In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.

Host: Marlene Mimi Maeusli, PhD. A recent Danish population-based study evaluating real-world outcomes of ibrutinib in relapsed or refractory mantle cell lymphoma (MCL) found lower efficacy and tolerability compared to clinical trials, particularly among older patients and those with high-risk disease features. In this AudioAbstract, ReachMD's Dr. Mimi Maeusli explains how this evidence is reshaping our view of ibrutinib's clinical utility.

Host: Marlene Mimi Maeusli, PhD. A recent Danish population-based study evaluating real-world outcomes of ibrutinib in relapsed or refractory mantle cell lymphoma (MCL) found lower efficacy and tolerability compared to clinical trials, particularly among older patients and those with high-risk disease features. In this AudioAbstract, ReachMD's Dr. Mimi Maeusli explains how this evidence is reshaping our view of ibrutinib's clinical utility.

Guest: Paola Marignani, PhD, EMBA While smoking remains a key risk factor for lung cancer, up to 25 percent of cases occur in people who have never smoked, leaving significant gaps in our understanding of causation and diagnostics. Dr. Paola Marignani explores emerging discoveries in gene variants unique to never-smokers, uncovered through single-cell RNA sequencing and machine learning. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.

Guest: Paola Marignani, PhD, EMBA While smoking remains a key risk factor for lung cancer, up to 25 percent of cases occur in people who have never smoked, leaving significant gaps in our understanding of causation and diagnostics. Dr. Paola Marignani explores emerging discoveries in gene variants unique to never-smokers, uncovered through single-cell RNA sequencing and machine learning. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.

Host: Ryan Quigley The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this means for screening, early diagnosis, care pathways, and equitable access to treatment.

Guest: John Cho, MD, PhD, FRCPC While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Guest: John Cho, MD, PhD, FRCPC Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Guest: Paola Marignani, PhD, EMBA Single-cell RNA sequencing is transforming our understanding of tumor heterogeneity in primary lung cancers by offering insights far beyond traditional bulk sequencing. In this program, Dr. Paola Marignani explores how advanced machine learning enables faster, more precise profiling of genetic diversity, predictive modeling for recurrence and drug resistance, and personalized treatment strategies. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.

Guest: John Cho, MD, PhD, FRCPC Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Guest: Paola Marignani, PhD, EMBA Single-cell RNA sequencing is transforming our understanding of tumor heterogeneity in primary lung cancers by offering insights far beyond traditional bulk sequencing. In this program, Dr. Paola Marignani explores how advanced machine learning enables faster, more precise profiling of genetic diversity, predictive modeling for recurrence and drug resistance, and personalized treatment strategies. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.

Guest: John Cho, MD, PhD, FRCPC While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Host: Ryan Quigley The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this means for screening, early diagnosis, care pathways, and equitable access to treatment.

Hear from experts in HIV care Beatriz Grinsztejn, MD, PhD, and Rosie Mnggibisa, MBChB, MPH, as they discuss their insights on some of the most clinically relevant new data presented at IAS 2025, including studies on: Gaps in care for adolescents and young adults living with HIVGlobal impact of funding cutsAntiretroviral therapy for treating HIVPatient management strategies for people living with HIV and obesityPresenters:Beatriz Grinsztejn, MD, PhDDirectorSTI/HIV Clinical Research LaboratoryEvandro Chagas National Institute of Infectious Diseases – FIOCRUZRio de Janeiro, BrazilRosie Mngqibisa, MBChB, MPHClinical DirectorPrincipal InvestigatorEnhancing Care FoundationDurban, South AfricaLink to full program: https://bit.ly/4otF8AR

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings.Program Abstracts: POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCLECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCLCADANCE-101: BGB-16673 BTK Degrader in R/R CLL/SLLInMIND: Tafasitamab, Lenalidomide, Rituximab in R/R FLSHR2554: Oral EZH2 Inhibitor in R/R PTCLSYRUS: AZD0486 Bispecific Antibody for R/R B-ALLPresenters:Max S. Topp, MDHead of Hematology and Clinical CAR-T Program LeadAssociated ProfessorMedinische Klinik und Poliklinkik IIUniversity of WurzburgWurzburg, GermanyPier Luigi Zinzani, MD, PhDProfessor of HematologyAlma Mater Studiorum- University of BolognaHead, “Seràgnoli” Institute of HematologyIRCCS Azienda Ospedaliero-Universitaria di BolognaDepartment of Medical and Surgical SciencesBologna University School of MedicineBologna, ItalyLink to full program:https://bit.ly/4obcJPI

In this episode, Kevin Kalinsky, MD, MS, FASCO, and Sara M. Tolaney, MD, MPH, discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting, including: DESTINY-Breast09: phase III trial of trastuzumab deruxtecan with or without pertuzumab vs THP as first-line treatment of HER2-positive advanced/metastatic breast cancerASCENT-04/KEYNOTE-D19: phase III trial of first-line sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in PD-L1–positive advanced TNBCSERENA-6: phase III trial of ctDNA-guided switch to camizestrant plus CDK4/6i vs continued AI plus CDK4/6i following ESR1 mutation emergence in HR-positive/HER2-negative advanced breast cancerINAVO120: OS from phase III study of first-line inavolisib/PBO plus palbociclib plus fulvestrant in PIK3CA-mutated, HR-positive/HER2-negative, endocrine-resistant advanced breast cancerPresenters:Kevin Kalinsky, MD, MS, FASCO​Professor of Medicine​Louisa and Rand Glenn Family Chair in Breast Cancer Research​Winship Cancer Institute​Emory UniversityAtlanta, Georgia​Sara M. Tolaney, MD, MPH​Chief, Breast Oncology​Dana-Farber Cancer Institute​Associate Professor of Medicine​Harvard Medical School​Boston, Massachusetts​Content based on an online CME program supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.Link to full program: https://bit.ly/4lFS4BC

Guest: John Bridges, MD, MS For children with rheumatic diseases, early diagnosis, personalized care, and multidisciplinary collaboration are critical for optimal long-term management. Join Dr. John Bridges, Assistant Professor in the Division of Pediatric Rheumatology at the University of Alabama at Birmingham Heersink School of Medicine, as he explains how access, timing, and collaboration shape pediatric rheumatology care. Dr. Bridges presented on this topic at the 2025 Congress of Clinical Rheumatology East conference.

In this episode, Chloe Orkin, MBChB, FRCP, MD, and Jean-Michel Molina, MD, PhD, discuss highlights from CCO's independent conference coverage of CROI 2025, including:Advances in HIV treatment based on results from CARESPotential HIV therapies in the pipeline, such as doravirine/islatravirEffects of broadly neutralizing antibodies on HIV treatment and cure Key clinical data on HIV and STI prevention obtained from PILLAR, HPTN 083, PURPOSE 1, and STOMPPresenters:Chloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesDean for Healthcare TransformationHonorary Consultant Physician, Barts Health NHS TrustFaculty of Medicine and DentistryQueen Mary University of LondonLondon, United KingdomJean-Michel Molina, MD, PhDProfessor of MedicineUniversity of Paris CiteDepartment of Infectious DiseasesSaint-Louis and Lariboisiere Hospitals, APHPParis, FranceLink to full program:bit.ly/3E1bAYQTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

The Word of the Day is Perspective (0:00-37:58) Eagles owner Jeffery Lurie addresses the media during the NFL's annual League Meetings, where he will discuss topics such as the Tush Push, Dallas Goedert, and the upcoming Parade. (37:58-40:46) Tyrone expresses gratitude for strong ownership, particularly in light of Jerry Jones providing another noteworthy soundbite for the media. (40:46-46:24) Jones remarked that agents do not influence the game on the field, clarifying that he did not intend to offend the league's agents. He asserts that he and the players are the primary factors affecting on-field performance. Follow The Station x.com/975TheFanatic instagram.com/975thefanatic/ https://www.facebook.com/975thefanatic/ Follow The Show x.com/975BestShowEver https://x.com/TyJohnsonNews https://x.com/rickybottalico https://x.com/sylvanakell Support the Show 975thefanatic.com/shows/the-best-show-

Guest: Sara Horst, MD, MPH, FACG While inflammatory bowel disease (IBD) does not typically cause significant problems in pregnancy, it's still essential to discuss potential impacts with patients and monitor them closely. Dr. Sara Horst, a Professor of Medicine at Vanderbilt University Medical Center, joins GI Insights to discuss important considerations for pregnant patients with IBD.

Guest: Shalini Prasad, PhD Guest: Sriram Muthukumar, PhD Host: Charles Turck, PharmD, BCPS, BCCCP With the constant ups and downs of inflammatory bowel disease (IBD), consistent monitoring can help provide patient-centric care. Dr. Shalini Prasad and Dr. Sriram Muthukumar, co-founders of EnLiSense, join GI Insights to discuss the wearable device they developed to track inflammation markers in IBD patients. Dr. Prasad is the Head of the Department of Bioengineering at the University of Texas at Dallas, and Dr. Muthukumar is the CEO of EnLiSense.

In this episode, we interview a handful of guests--presenters, first timers, and repeat attendees from the 2025 ALI-CLE Eminent Domain and Land Valuation Conference. Note: Next Year's conference will be in Savannah, GA.    Links: ALI-CLE 2025 Conference Information: https://www.ali-cle.org/course/Eminent-Domain-and-Land-Valuation-Litigation-2025-CG204 Guest Chris Clough: https://www.barronadler.com/attorneys/christopher-clough/ Guest Angela Misch: https://www.gunster.com/people/angela-j-misch  Guest Clint Schumacher: https://www.dawsonsodd.com/attorneys/clint-schumacher/  Guest Elizabeth Sockwell: https://www.millermillercanby.com/attorney/elizabeth-r-sockwell/

In this episode, Jean-Michel Molina, MD, PhD, and Joseph J. Eron, Jr., MD, discuss results from key clinical trials on HIV prevention and treatment as well as sexually transmitted infection (STI) prevention presented at IDWeek and Glasgow 2024, including:PURPOSE 1 and 2 comparing lenacapavir injection vs oral TDF/FTCTRIO Health Cohort and OPERA examining long-acting cabotegravir as PrEPDOLCE comparing DTG/3TC as first-line therapy in treatment-naive patients with HIVPRIDOX evaluating the use of DoxyPEP on STI incidence in men who have sex with men on PrEPPresenters:Jean-Michel Molina, MD, PhDProfessor of Infectious DiseasesUniversity of Paris CitéHead of the Department of Infectious DiseasesHospital Saint-Louis and lariboisièreParis, FranceJoseph J. Eron, Jr., MDProfessor of Medicine, School of MedicineHerman and Louise Smith Distinguished ProfessorChief, Division of Infectious DiseasesDirector, Clinical Core, UNC Center for AIDS ResearchAdjunct Professor of Epidemiology, Gillings School of Global Public HealthUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaLink to full program: https://bit.ly/3BBaZvJ

(0:00-11:53) Tyrone, Ricky and Sylvana do not need any more proof from the Eagles that they are the best team in the league. The Carolina game was stinker, but they rebounded strong to win vs Pittsburgh. (11:53-40:15) Coverage of the Nick Sirianni press conference (40:15-45:06) Reaction to Nick Sirianni press conference Follow The Station x.com/975TheFanatic instagram.com/975thefanatic/ https://www.facebook.com/975thefanatic/ Follow The Show x.com/975BestShowEver https://x.com/TyJohnsonNews https://x.com/rickybottalico https://x.com/sylvanakell Support the Show 975thefanatic.com/shows/the-best-show-

On this week’s Mormon Newscast we take a look at LDS General Conference and all its happening. Who spoke that stands out? What did they say? And what else happened around conference? Help support RFM and Bill Reel with The Mormon Newscast in making Latter-day News informative & entertaining shining a light on truth with… Read More »General Conference Coverage [The Mormon Newscast 039] The post General Conference Coverage [The Mormon Newscast 039] appeared first on Mormon Discussions Podcasts - Full Lineup.